Biomea Fusion (BMEA)
Develops oral small-molecule medicines for diabetes and obesity.
Something off on this page? Send us feedback.
Develops clinical-stage oral medicines centered on icovamenib for diabetes and BMF-650 for obesity. Its business has no approved products or revenue and depends on clinical development and regulatory progress.
Develops oral covalent small-molecule medicines through its FUSION System. The current pipeline centers on icovamenib, a selective covalent menin inhibitor studied in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist for obesity.
Internal oncology development has ended, while the company seeks partners for those assets and concentrates its resources on metabolic medicine. The strategy moves resource allocation from a prior oncology focus while retaining its small-molecule discovery approach.
With no approved products or revenue, the operating model depends on clinical development and regulatory progress for the remaining programs.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $34.8M · Total debt $877.0K · Total assets $36.9M · Shareholders' equity $12.1M
- Revenue
- $0
- Operating income
- −$12.8M
- Net income
- −$8.3M
No dividends on record.
| Institutions68 holders · as of Mar 31, 2026 | 33.60% | 24.35M shares | |
| Insiders3 holders · as of Feb 6, 2026 | 2.78% | 2.02M shares | |
| Strategic holders2 holders · as of Feb 17, 2026 | 16.00% | 11.60M shares | |
| Otherremainder | 47.62% | 34.52M shares |
72.48M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 12.16% | 8.81M | 13Fas of Mar 31, 2026 |
CVI Investments, Inc.Strategic | 10.83% | 7.85M | 13Gfiled Feb 17, 2026 ↗ |
Blue Owl Capital Holdings LPInstitution | 6.14% | 4.45M | 13Gfiled Feb 12, 2026 ↗ |
Janus Henderson Group PLCStrategic | 5.17% | 3.75M | 13Gfiled Dec 8, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 3.58% | 2.60M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 11, 2025 | Rainer M. Erdtmann | director, officer: See Remarks | +30,000 | $1.43 |
| Dec 2, 2025 | Michael J.M. Hitchcock | director, officer: Interim CEO | +100,000 | $0.9918 |
| Nov 28, 2025 | Rainer M. Erdtmann | director, officer: See Remarks | +40,000 | $1.10 |
| Dec 1, 2025 | Rainer M. Erdtmann | director, officer: See Remarks | +10,000 | $1.05 |
- Eli Lilly
Oral GLP-1 medicine for obesity and type 2 diabetes
- Novo Nordisk (ADR)
Oral semaglutide offerings in obesity and type 2 diabetes
- Viking Therapeutics
Oral GLP-1/GIP dual agonist in advanced obesity development
- Structure Therapeutics (ADR)
Oral small-molecule GLP-1 candidate for obesity
- Vertex Pharmaceuticals
Stem-cell islet replacement for type 1 diabetes
- Sana Biotechnology
Hypoimmune islet-cell therapy for type 1 diabetes
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biomea Fusion | $1.93 | −0.26% | $139.9M | — | — | — | — |
| Eli Lilly | $1,164.00 | +0.40% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novo Nordisk (ADR) | $47.81 | +2.26% | $207.69B | 11.5 | 18.8 | 4.1 | +0.0% |
| Viking Therapeutics | $33.42 | −0.24% | $3.91B | — | — | — | — |
| Structure Therapeutics (ADR) | $48.90 | +2.37% | $2.75B | — | — | — | — |
| Vertex Pharmaceuticals | $556.75 | +0.01% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Sana Biotechnology | $3.95 | +1.28% | $1.08B | — | — | — | — |
| Median | 32.4 | 28.4 | 11.2 | +12.5% |